55 related articles for article (PubMed ID: 28721639)
1. Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
Breast Cancer Res Treat; 2017 Sep; 165(2):471. PubMed ID: 28721639
[No Abstract] [Full Text] [Related]
2. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
Breast Cancer Res Treat; 2016 Apr; 156(3):507-515. PubMed ID: 27083178
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy.
EL Baiomy MA; El Kashef WF
Asian Pac J Cancer Prev; 2017 Feb; 18(2):507-513. PubMed ID: 28345838
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Gonçalves A
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
[TBL] [Abstract][Full Text] [Related]
7. Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer.
Baba M; Takahashi M; Yamashiro K; Yokoo H; Fukai M; Sato M; Hosoda M; Kamiyama T; Taketomi A; Yamashita H
Surg Today; 2016 Jul; 46(7):843-51. PubMed ID: 26494004
[TBL] [Abstract][Full Text] [Related]
8. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Agrawal LS; Mayer IA
Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy.
Zhang J; Fan M; Xie J; Wang Z; Wang B; Zhang S; Wang L; Cao J; Tao Z; Li T; Hu X
Oncotarget; 2015 Dec; 6(40):43135-43. PubMed ID: 26447756
[TBL] [Abstract][Full Text] [Related]
10. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
Ellingson MS; Hart SN; Kalari KR; Suman V; Schahl KA; Dockter TJ; Felten SJ; Sinnwell JP; Thompson KJ; Tang X; Vedell PT; Barman P; Sicotte H; Eckel-Passow JE; Northfelt DW; Gray RJ; McLaughlin SA; Moreno-Aspitia A; Ingle JN; Moyer AM; Visscher DW; Jones K; Conners A; McDonough M; Wieben ED; Wang L; Weinshilboum R; Boughey JC; Goetz MP
Breast Cancer Res Treat; 2015 Sep; 153(2):435-43. PubMed ID: 26296701
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
13. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
14. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
16. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
Hurley J; Reis IM; Rodgers SE; Gomez-Fernandez C; Wright J; Leone JP; Larrieu R; Pegram MD
Breast Cancer Res Treat; 2013 Apr; 138(3):783-94. PubMed ID: 23542956
[TBL] [Abstract][Full Text] [Related]
17. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
[TBL] [Abstract][Full Text] [Related]
18. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Lederer B; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kümmel S; Loibl S; Paepke S; Untch M; von Minckwitz G; Schneeweiss A
Eur J Cancer; 2016 Jan; 53():65-74. PubMed ID: 26693900
[TBL] [Abstract][Full Text] [Related]
19. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
20. [Platinum-based chemotherapy in triple negative breast cancer].
Eckstein N; Haas B
Dtsch Med Wochenschr; 2012 Feb; 137(7):333-6. PubMed ID: 22318849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
